Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frondanol in Inflammatory Bowel Disease
NCT05194007Phase 3Completed
- Sponsor
- Mohammed Bin Rashid University of Medicine and Health Sciences
- Start
- Feb 2022
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's colitis (2 arms), sponsored by Mohammed Bin Rashid University of Medicine and Health Sciences. Primary endpoints: Change in plasma levels of cytokines at 6 months, Change in plasma levels of marker of inflammation at 6 months and 2 more. Started Feb 2022; status: completed.
02
Conditions
inflammatory bowel disease (IBD)ulcerative colitis (UC)Crohn's colitis
Beyond the preview
Go deeper on NCT05194007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194007.